BeiGene Ltd.
(NASDAQ : BGNE)

( )
BGNE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -2.66%567.042.7%$653.70m
GILDGilead Sciences, Inc. -2.15%58.721.0%$566.34m
AMGNAmgen, Inc. -3.17%216.381.3%$560.76m
VRTXVertex Pharmaceuticals, Inc. -1.81%208.341.9%$523.63m
MRNAModerna, Inc. -6.98%65.740.0%$419.54m
ILMNIllumina, Inc. -3.75%309.693.5%$406.75m
EXASEXACT Sciences Corp. -2.75%127.5220.7%$286.06m
ALXNAlexion Pharmaceuticals, Inc. -4.29%114.852.0%$257.36m
BIIBBiogen, Inc. -4.32%244.261.7%$252.72m
NVAXNovavax, Inc. -9.22%81.3396.5%$248.68m
BNTXBioNTech SE -7.64%77.540.0%$195.34m
SGENSeagen Inc. -1.05%194.856.0%$148.85m
SRNESorrento Therapeutics, Inc. -8.04%7.091.4%$139.14m
CRSPCRISPR Therapeutics AG -3.48%94.710.6%$121.93m
SRRKScholar Rock Holding Corp. 44.67%43.430.0%$104.54m

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.